Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo (Q39345885)

11 September 2017

title

Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo (English)

1 reference

11 September 2017

Marina Zaitseva

1

1 reference

11 September 2017

Tatiana Romantseva

2

1 reference

11 September 2017

Ksenia Blinova

3

1 reference

11 September 2017

Joel Beren

4

1 reference

11 September 2017

Lev Sirota

5

1 reference

11 September 2017

Debbie Drane

6

1 reference

11 September 2017

Hana Golding

7

1 reference

11 September 2017

language of work or name

English

0 references

publication date

15 May 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

30

1 reference

11 September 2017

issue

32

1 reference

11 September 2017

page(s)

4859-4865

1 reference

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Recent advances in the discovery and delivery of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Toll-like receptors and dendritic cells: for whom the bug tolls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Pathogen recognition and innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

How do adjuvants work? Important considerations for new generation adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Vaccine adjuvants: scientific challenges and strategic initiatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Adjuvants--a balance between toxicity and adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Design and selection of vaccine adjuvants: animal models and human trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Of mice and not men: differences between mouse and human immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

New adjuvants: EU regulatory developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Cytokines and fever. Mechanisms and sites of action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

The onset of fever: new insights into its mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Targeting of Toll-like receptors: a decade of progress in combating infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Regulation of Toll-like receptors in human monocytes and dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

TLR signaling tailors innate immune responses in human microglia and astrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Human monocytoid cell lines as indicators of endotoxin: comparison with rabbit pyrogen and Limulus amoebocyte lysate assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

International validation of novel pyrogen tests based on human monocytoid cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

New horizons in adjuvants for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Resiquimod and other immune response modifiers as vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Bidirectional transport of interleukin-1 alpha across the blood-brain barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

A phase I clinical trial of recombinant human tumor necrosis factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

The predictive value of interleukin-8 (IL-8) in hospitalised patients with fever and chemotherapy-induced neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Bacterial lipopolysaccharide fever is initiated via Toll-like receptor 4 on hematopoietic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

Cellular and molecular bases of the initiation of fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.002

10.1016/J.VACCINE.2012.05.002

7 January 2021

Identifiers

DOI

1 reference

11 September 2017

1 reference